FUNDAMENTALS · Fundamentals · CA Healthcare

NervGen Pharma Corp. Common stock (NGEN) Fundamentals 2026 — Revenue Analysis | SniperIQ

NervGen Pharma Corp. Common stock (NGEN) is a CA-listed Healthcare company in Biotechnology with a market capitalization of

41M, trading at
.72 on the NASDAQ. This SniperIQ fundamentals page covers NervGen Pharma Corp. Common stock's valuation, profitability (net margin 0.0%), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap
41M
Net Margin0.0%

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is NervGen Pharma Corp. Common stock's market cap?

NervGen Pharma Corp. Common stock (NGEN) has a market capitalization of approximately

41M, trading at
.72 on the NASDAQ. Market cap moves with the live share price.

What is NervGen Pharma Corp. Common stock's P/E ratio?

NervGen Pharma Corp. Common stock's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 108.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is NervGen Pharma Corp. Common stock?

NervGen Pharma Corp. Common stock runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

Does NervGen Pharma Corp. Common stock pay a dividend?

NervGen Pharma Corp. Common stock does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is NervGen Pharma Corp. Common stock financially healthy?

NervGen Pharma Corp. Common stock carries a debt-to-equity ratio of 0.00x and a current ratio of 1.16x, with a market beta of 0.69. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is NervGen Pharma Corp. Common stock a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For NervGen Pharma Corp. Common stock (NGEN) the key facts are: market cap

41M, 52-week range 1.59-6.3. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track NervGen Pharma Corp. Common stock's full fundamentals live

Get NervGen Pharma Corp. Common stock's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: EBR Systems (EBR) fundamentals · TuHURA Biosciences (HURA) fundamentals · Cardiol Therapeutics (CRDL) fundamentals · Connect Biopharma Holdings (CNTB) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons